Risedronic acid 利塞膦酸; Risedronate,98.0%

产品编号:Bellancom-B0148| CAS NO:105462-24-6| 分子式:C7H11NO7P2| 分子量:283.11

Risedronic acid(Risedronate)能抑制破骨细胞介导的骨重吸收。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-B0148
720.00 杭州 北京(现货)
Bellancom-B0148
2550.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Risedronic acid 利塞膦酸; Risedronate

产品介绍 Risedronic acid(Risedronate)能抑制破骨细胞介导的骨重吸收。
生物活性

Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption. Target: Others Risedronate, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy . The administration of 20 and 25 mg/kg risedronate for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls .

体外研究
体内研究
体内研究
性状Solid
溶解性数据
In Vitro: 

0.1 M NaOH : 11 mg/mL (38.85 mM; ultrasonic and adjust pH to 7 with NaOH)

H2O : 0.67 mg/mL (2.37 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.5322 mL 17.6610 mL 35.3220 mL
5 mM 0.7064 mL 3.5322 mL 7.0644 mL
10 mM 0.3532 mL 1.7661 mL 3.5322 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


海关编码 2933399090

~98%

105462-24-6结构式

105462-24-6

文献:JUBILANT ORGANOSYS LIMITED Patent: WO2006/51553 A1, 2006 ; Location in patent: Page/Page column 8 ;

~81%

105462-24-6结构式

105462-24-6

文献:FLEMING LABORATORIES LIMITED Patent: WO2009/34580 A1, 2009 ; Location in patent: Page/Page column 7 ;

~82%

105462-24-6结构式

105462-24-6

文献:ZAKLADY FARMACEUTYCZNE S.A.; POLITECHNIKA GDANSKA Patent: WO2006/71128 A1, 2006 ; Location in patent: Page/Page column 4; 5 ;

~%

105462-24-6结构式

105462-24-6

文献:WO2008/58722 A1, ; Page/Page column 11-12 ;

~%

105462-24-6结构式

105462-24-6

文献:WO2008/44245 A2, ; Page/Page column 5 ;

~%

105462-24-6结构式

105462-24-6

文献:US5391743 A1, ;

~%

105462-24-6结构式

105462-24-6

文献:Phosphorus, Sulfur and Silicon and the Related Elements, , vol. 188, # 1-3 p. 39 - 41

服务热线

13911702513
18601927057

微信客服